DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS FY 30 APRIL 2026

DXS International returned to a £61,839 FY2026 profit from a £94,750 loss, although revenue declined 5.2% to £3.29m and the profit was primarily supported by a £157,791 R&D tax credit. Cash at bank fell to £83,610 from £428,957, while available liquidity including unused debtor-factoring drawdowns was £393,258. All customers renewed for 18 months, and management sees a potential >£1m annual recurring-revenue upsell opportunity from NHS ICB consolidation, but timing depends on the new NHS framework and is expected no earlier than January 2027.

Analysis

DXSP’s apparent earnings inflection is not yet an operating inflection: pre-tax losses persist and the reported profit relies on a tax-credit benefit. More importantly, cash conversion deteriorated sharply, leaving the business dependent on receivables financing and continued creditor/insider support. For a thinly traded AQSE issuer, this shifts the near-term valuation debate from recurring-revenue optionality to whether working-capital headroom survives the procurement gap through the next NHS decision cycle.

The 18-month renewals improve revenue visibility but also defer the most meaningful monetisation event. The upside case is operational leverage: a modest incremental software deployment base should carry high contribution margins because the product, clinical content and support infrastructure are already largely in place. However, the cited upsell opportunity should be discounted heavily until a consolidated ICB actually standardises procurement; consolidation can create larger contracts, but it also centralises buyer power, elongates sales cycles and raises the risk of a single-platform tender favoring better-capitalised NHS IT vendors.

The January-October 2027 product, framework and pricing milestones create an unusually binary 6-12 month catalyst path. Consensus may focus on the gross potential of the patient-base expansion while overlooking that an October framework delay would leave DXSP facing another period of low cash balances, interest expense and potential equity issuance. The carrying value of capitalised development is also material relative to equity; failure of NexGen SMART Referrals or ExpertCare pilots to convert into contracted revenue would increase impairment risk and compress any multiple assigned to the software platform.

No broad read-through exists for listed UK healthcare technology: DXSP is too small and its NHS exposure is idiosyncratic. The appropriate signal is therefore contract conversion rather than the headline return to profit—specifically, signed ICB-wide deployments, upfront implementation cash receipts, and operating cash flow turning positive before the planned pricing reset.

Key Decisions for Investors

• Maintain no core position in DXSP pending evidence of a funded runway: require cash at bank plus committed undrawn financing to cover at least 12 months of operating outflows, rather than relying on management’s available-cash presentation. Reassess on the next interim cash-flow disclosure.
• For a specialist microcap sleeve only, place a conditional long watch order after the first signed ICB standardisation contract or disclosed NexGen/ExpertCare conversion in Q1-Q2 2027. Size at no more than 25-50 bps of NAV given AQSE liquidity; the upside is a rerating on proof of ARR conversion, while downside remains substantial if the catalyst slips.
• Do not underwrite the 2027 price increase or the stated upsell opportunity in base-case revenue forecasts until the replacement NHS framework is published and procurement eligibility is confirmed. Treat an extension beyond October 2027, or a further need for debtor-facility usage/related-party funding, as thesis falsifiers.
• Monitor three hard triggers: operating loss excluding tax credits, monthly cash burn/receivables days, and any impairment review of capitalised development. A further negative operating cash-flow period without contracted incremental ARR should move DXSP from watchlist to avoid, regardless of reported EPS.